MITF Modulates Therapeutic Resistance through EGFR Signaling

[1]  Ulrich Keilholz,et al.  Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway , 2015, Targeted Oncology.

[2]  Q. Zhan,et al.  ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. , 2014, Cancer research.

[3]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[4]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[5]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[6]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[7]  R. Marais,et al.  Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma , 2012, Journal of the National Cancer Institute.

[8]  R. Word,et al.  Hypoxia and PGE(2) regulate MiTF-CX during cervical ripening. , 2012, Molecular endocrinology.

[9]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[10]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[11]  S. Estrem,et al.  Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma* , 2012, The Journal of Biological Chemistry.

[12]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[13]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[14]  K. Flaherty,et al.  p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. , 2012, The Journal of investigative dermatology.

[15]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[16]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[17]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[18]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[19]  C. Der.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2010 .

[20]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[21]  J. Zha,et al.  Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. , 2008, Cancer research.

[22]  M. Ramoni,et al.  Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. , 2006, The Journal of investigative dermatology.

[23]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[24]  T. Joh,et al.  IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. , 2005, Cytokine.

[25]  V. Hearing,et al.  Involvement of ITF2 in the Transcriptional Regulation of Melanogenic Genes* , 2001, The Journal of Biological Chemistry.